LUMINOS-103: A Basket Trial Evaluating the Safety and Efficacy of Lerapolturev (PVSRIPO) and Lerapolturev in Combination With Anti-PD-1/L1 Checkpoint Inhibitors in Patients With Advanced Solid Tumors
Latest Information Update: 11 Apr 2024
At a glance
- Drugs Lerapolturev (Primary) ; Programmed cell death 1 receptor antagonists; Programmed cell death-1 ligand-1 inhibitors
- Indications Bladder cancer; Carcinoma; Head and neck cancer; Hypopharyngeal cancer; Laryngeal cancer; Mouth neoplasm; Pharyngeal neoplasms; Solid tumours; Squamous cell cancer; Urogenital cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms LUMINOS-103
- Sponsors Istari Oncology
- 04 Apr 2024 Status changed from recruiting to active, no longer recruiting.
- 31 Jan 2023 According to an Istari Oncology media release, recruiting for the NMIBC substudy is ongoing and is expected to reach full enrollment by mid-year.
- 31 Jan 2023 According to an Istari Oncology media release, first patient has been dosed via intravesicular instillation in the non-muscle-invasive bladder cancer (NMIBC) cohort of the substudy of this trial.